Mr. Stephen A. Stamp has been appointed as Chief Financial Officer, Director of the Company, with effect from 11 January 2016. Stephen Stamp brings to Ergomed more than 30 years of experience in corporate finance and general management in both public and private companies in the UK and the USA. Stephen joins Ergomed from US-based AssureRx Health, Inc, a personalised medicine and bio-informatics company where he was CFO. Prior to this he was CFO of EZCORP, Inc., a consumer financial services company and Chief Operating Officer and CFO at Xanodyne Pharmaceuticals, Inc, a specialty pharmaceutical company. Stephen has substantial experience working in UK-listed companies. He was Group Finance Director at Regus Plc, where he successfully listed the Company on London Stock Exchange Main Market and NASDAQ in October 2000. Prior to this he was Group Finance Director at Shire Pharmaceuticals, where he led the IPO on London Stock Exchange as well as a number of major acquisitions and financings. During his time at the Company, Shire's market capitalisation increased from GBP20 million to GBP3.1 billion. Earlier in his career, Stephen was an investment banker with Lazard in London, advising mainly public companies on cross-border M&A and corporate finance. Prior to Lazard, he worked for KPMG in London where he qualified as a Chartered Accountant.

General management,consumer financial serviceS,pharmaceuticalS,